The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships

Clinical Pharmacokinetics

Volumn 45, Issue 5, 2006, Pages 433-448

  Fagiolino, Pietro ^a   Eiraldi, Rosa ^a   V́azquez, Marta ^a  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANXIOLYTIC AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CARBAMAZEPINE; CATECHOLAMINE DERIVATIVE; CYTOCHROME P450 ISOENZYME; DIAZEPAM; DIGOXIN; GENTAMICIN; HYPNOTIC AGENT; ISOPRENALINE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; KETOPROFEN; METHYLXANTHINE DERIVATIVE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROPRANOLOL; PROPRANOLOL DERIVATIVE; PSYCHOTROPIC AGENT; THEOPHYLLINE; XENOBIOTIC AGENT;

AGE DISTRIBUTION; AGING; AUTONOMIC NERVOUS SYSTEM; BLOOD FLOW; BLOOD PRESSURE; BLOOD VESSEL; CARDIOTOXICITY; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR SYSTEM; CHRONOLOGY; CIRCADIAN RHYTHM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG SENSITIVITY; DRUG TISSUE LEVEL; DRUG TRANSPORT; EXERCISE; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; INFUSION PUMP; KIDNEY BLOOD FLOW; NONHUMAN; ORGAN; PLASMA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SOLUTE; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; TISSUE; WATER LOSS;

AGING; CARDIOVASCULAR PHYSIOLOGY; DRUG THERAPY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 33646137387     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645050-00001     Document Type: Review

References (71)

1. Levy G. Predicting effective drug concentrations for individual patients: determinants of pharmacodynamics variability. Clin Pharmacokinet 1998; 34: 323-33
2. Ḧammerlein A, Derendorff H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet 1998; 35: 49-64
3. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (part I). Clin Pharmacokinet 1991; 21: 165-77
4. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (part II). Clin Pharmacokinet 1991; 21: 262-73
5. Turnheim K. Drug dosage in the elderly: is it rational? Drugs Aging 1998; 13: 357-79
6. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38: 843-53
7. Ritschel WA. Chronopharmacokinetics. Pharm Internat 1984; 5: 116-22
8. Lemmer B. Chronopharmacological aspects of PK/PD modeling. Int J Clin Pharmacol Ther 1997; 35: 458-64
9. Redfern P, Lemmer B, editors. Handbook of experimental pharmacology: physiology and pharmacology of biological rhythms. Vol. 125. Berlin: Springer-Verlag, 1997
10. Eichler HG, Müller M. Drug distribution: the forgotten relative in clinical pharmacokinetics. Clin Pharmacokinet 1998; 34: 95-9
11. Word Health Organization (WHO). International programme on chemical safety. Environmental health criteria 144. Principles of evaluating chemical effects on the aged population. Geneva, 1993 [online]. Available from URL: http://www.inchem.org/documents/ehc/ehc/ehc144.htm [Accessed 2004 Oct 19]
12. Cheitlin MD. Cardiovascular physiology: changes with aging. Am J Geriatr Cardiol 2003; 12: 9-13
13. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163-84
14. McElnay JC, D'Arcy PF. Age and genetic factors in drug interactions. In: D'Arcy PF, McElnay JC, Welling PG, editors. Handbook of experimental pharmacology: mechanisms of drug interactions. Vol. 122. Berlin: Springer-Verlag, 1996: 279-304
15. Le Couteur DG, McLean AJ. The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34: 359-73
16. Steimer JL, Ebelin ME, Van Bree J. Pharmacokinetic and pharmacodynamics data and models in clinical trials. Eur J Drug Metab Pharmacokinet 1993; 18: 61-76
17. Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/ pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 1997; 35: 401-13
18. Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 1997; 62: 453-63
19. Fagiolino P. The influence of cardiac output distribution on the tissue/plasma drug concentration ratio. Eur J Drug Metab Pharmacokinet 2002; 27: 79-81
20. Fagiolino P, Wilson F, Samaniego E, et al. In vitro approach to study the influence of the cardiac output distribution on drug concentration. Eur J Drug Metab Pharmacokinet 2003; 28: 147-53
21. Fagiolino P. Multiplicative dependence of the first order rate constant and its impact on clinical pharmacokinetics and bioequivalence. Eur J Drug Metab Pharmacokinet 2004; 29: 43-9
22. Olano I, V́azquez M, Fagiolino P. Chronopharmacokinetics of carbamazepine and its metabolite 10,11-epoxide. J Pharm Clin 1998; 17: 153-6
23. Fagiolino P. Monitorización de f́armacos en saliva: aplicaciones biofarmacéuticas, farmacocinéticas y terapéuticas. Montevideo: Comisión Sectorial de Investigación Científica (CSIC) - Universidad de la Reṕublica O. del Uruguay, 1999
24. Fagiolino P, Duré MC, Vázquez M. Sympathetic tone evaluation in patients treated with phenytoin and carbamazepine [in Spanish]. Acta Farm Bonaerense 2000; 19: 119-24
25. Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 2001; 18: 837-51
26. Kaminsky LS, Zhang QY. The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 2003; 31: 1520-5
27. Gibbs MA, Hosea NA. Factors affecting the clinical development of cytochrome P450 3A substrates. Clin Pharmacokinet 2003; 42: 969-84
28. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005; 44: 33-60
29. Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999; 51: 135-58
30. von Richter O, Burk O, Fromm MF, et al. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172-83
31. Kivisto KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundamental Clin Pharmacol 2004; 18: 621-6
32. Hanratty CG, McGlinchey P, Johnston GD, et al. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging 2000; 17: 353-62
33. Labaune JP. Pharmacocinétique: principes fondamentaux. Paris: Masson SA, 1984
34. Koren G. Clinical pharmacokinetic significance of the renal tubular secretion of digoxin. Clin Pharmacokinet 1987; 13: 334-47
35. Timmis GC, Westveer DC, Nelson TA, et al., editors. Congestive heart failure and pulmonary edema, digitalis. In: Cardiovascular Review 1984. Orlando (FL): Academic Press, 1984: 521
36. Newton R, Broughton LJ, Lind MJ, et al. Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol 1981; 21: 45-52
37. Tang-Liu DDS, Williams RL, Riegelman S. Nonlinear theophylline elimination. Clin Pharmacol Ther 1982; 31: 358-69
38. Giessmann T, May K, Modes C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 2004; 76: 192-200
39. B́elanger PM, Bruguerolle B, Labrecque G. Rhythms in pharmacokinetics: absorption, distribution, metabolism and excretion. In: Redfern P, Lemmer B, editors. Handbook of experimental pharmacology, vol. 125: physiology and pharmacology of biological rhythms. Berlin: Springer-Verlag, 1997: 177-204
40. Lemmer B, Sheidel B, Behne S. Chronopharmacokinetics and chronopharmacodynamics of cardiovascular active drugs: propranolol, organic nitrates, nifedipine. Ann N Y Acad Sci 1991; 618: 166-81
41. Lemmer B, Scheidel B, Blume H, et al. Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects. Eur J Clin Pharmacol 1991; 40: 71-5
42. Zerbe H, Luckow V, Cawello W, et al. Isosorbide-5-nitrate sustained-release pellets: an example of computer-supported drug development. Pharm Res 1985; 3: 30-6
43. St-Pierre MV, Spino M, Isles AF, et al. Temporal variation in the disposition of theophylline and its metabolites. Clin Pharmacol Ther 1985; 38: 89-95
44. a edición. Madrid: Harcourt SA, 2000: 435-43
45. Decousus H, Ollagnier M, Cherrah Y, et al. Chronokinetics of ketoprofen infused intravenously at a constant rate. Ann Rev Chronopharmacol 1986; 3: 321-4
46. a edición. Barcelona: Masson SA, 2003: 375-408
47. Guyton AC, Hall JE. Texbook of medical physiology. 9th ed. [in Spanish]. Mexico: McGraw-Hill Interamericana Editors, 1997: 343-60
48. Dickson CJ, Schwartzman MS, Bertino JS. Factors affecting aminoglycoside disposition: effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics. Clin Pharmacol Ther 1986; 39: 325-8
49. van Acker BA, Koomen GC, Koopman MG, et al. Discrepancy between circadian rhythms of inulin and creatinine clearance. J Lab Clin Med 1992; 120: 400-10
50. Koopman MG, Koomen GC, Krediet RT, et al. Circadian rhythm of glomerular filtration rate in normal individuals. Clin Sci 1989; 77: 105-11
51. Bleyzac N, Allard-Latour B, Laffont A, et al. Diurnal changes in the pharmacokinetic behavior of amikacin. Ther Drug Monit 2000; 22: 307-12
52. Voogel AJ, Koopman MG, Augustinus AM, et al. Circadian rhythms in systemic hemodynamics and renal function in healthy subjects and patients with nephritic syndrome. Kidney Int 2001; 59: 1873-80
53. Bruguerolle B. Chronopharmacokinetics: current status. Clin Pharmacokinet 1998; 35: 83-94
54. Wedlund PJ, Levy RH. Time-dependent kinetics VII: effect of diurnal oscillations on the time course of carbamazepine autoinduction in the rhesus monkey. J Pharm Sci 1983; 72: 905-9
55. Miura T, Kojima R, Sugiura Y, et al. Effect of aging on the incidence of digoxin toxicity. Ann Pharmacother 2000; 34: 427-32
56. Sowinski K, Forrest A, Wilton J, et al. Effect of aging on atenolol pharmacokinetics and pharmacodynamics. J Clin Pharmacol 1995; 35: 807-14
57. van Baak MA. Influence of exercise on the pharmacokinetics of drugs. Clin Pharmacokinet 1990; 19: 32-43
58. Jogestrand T, Sundqvist K. Effect of physical exercise on the digoxin concentrations in skeletal muscle and serum in man. Clin Physiol 1981; 1: 99-104
59. Joreteg T, Jogestrand T. Physical exercise and digoxin binding to skeletal muscle: relation to exercise intensity. Eur J Clin Pharmacol 1983; 25: 585-8
60. Joreteg T, Jogestrand T. Physical exercise and binding of digoxin to skeletal muscle: effect of activation frequency. Eur J Clin Pharmacol 1984; 27: 567-70
61. Jorgestrand T, Andersson K. Effect of physical exercise on the pharmacokinetics of digoxin during maintenance treatment. J Cardiovasc Pharmacol 1989; 14: 73-6
62. Schmidt TA, Bundgaard H, Olesen HL, et al. Digoxin affects potassium homeostasis during exercise in patients with heart failure. Cardiovasc Res 1995; 29: 506-11
63. Serafin WE. Fármacos utilizados para el tratamiento del asma. In: Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. [in Spanish]. México: McGraw-Hill Interamericana Editores SA, 1996: 707-31
64. Tang-Liu DDS, Tozer TN, Riegelman S. Urine flow-dependence of theophylline renal clearance in man. J Pharmacokinet Biopharm 1982; 10: 351-64
65. Trnavska Z, Rejholec V, Elis J, et al. Comparative pharmacokinetic analysis of theophylline in serum and saliva. Int J Clin Pharm Res 1987; 7: 329-35
66. Shah VP, Riegelman S. GLC determination of theophylline in biological fluids. J Pharm Sci 1974; 63: 1283-5
67. Ishizaki T, Kubo M. Incidence of apparent Michaelis-Menten kinetic behavior of theophylline and its parameter (Vmax and Km) among asthmatic children and adults. Ther Drug Monit 1987; 9: 11-20
68. Tang-Liu DDS, Williams RL, Riegelman S. Nonlinear theophylline elimination. Clin Pharmacol Ther 1982; 31: 358-69
69. Payssé H, Fagiolino P, Vázquez M, et al. Preliminary study of the theophylline chronopharmacokinetics by salivary assay [in French]. J Pharm Clin 1997; 16: 60-4
70. Orosa E, Payssé H, Mérola J, et al. Incidence of the kinetics of nonlinear elimination in the posology with theophylline [in Spanish]. Rev OFIL 1993; 3: 18-21
71. Le Couteur DG, Fraser R, Hilmer S, et al. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005; 44: 187-200